ERBB2 and ovarian carcinoma: Trastuzumab targets human epidermal growth factor receptor 2 (HER2), a protein involved in cell proliferation that is overexpressed in multiple tumors [e.g., between 20 and 30% of breast cancers (132), and between 15 and 30% of ovarian cancers (133)].